Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction
Ureteral Obstruction
About this trial
This is an interventional treatment trial for Ureteral Obstruction focused on measuring Tolterodine, Tamsulosin, Ureteral Obstruction
Eligibility Criteria
Inclusion Criteria:
- Patients with unilateral ureteral stent placement for urolithiasis
Exclusion Criteria:
- Pre-existing lower urinary tract symptoms
- Active urinary tract infection
Contraindication to anticholinergic medication
- Prior hypersensitivity or allergy to tolterodine
- Patients with severe hepatic impairment (Child-Pugh Class C)
- Patients with uncontrolled close (narrow) angle glaucoma
- Patients with urinary retention
- Current anticholinergic use
- Chronic pelvic pain syndromes (e.g. acute/chronic prostatitis, interstitial cystitis)
- Women who are pregnant or nursing
- Under 18 years of age
- Prior hypersensitivity or allergy to tolterodine
- Patients with severe hepatic impairment (Child-Pugh Class C)
- Patients with uncontrolled close (narrow) angle glaucoma
- Patients with urinary retention
- Unable to provide informed consent
Sites / Locations
- University of Wisconsin
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Experimental
Active Comparator
Experimental
Tamsulosin plus placebo 7-day treatment
Tamsulosin plus Tolterodine ER 7-day treatment
Tamsulosin plus placebo 21-day treamtnet
Tamsulosin plus Tolterodine ER 21-day treatment
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms. Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity.
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms. Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity.